Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Canada
  4. Bourse de Toronto
  5. NervGen Pharma Corp.
  6. Summary
    NGEN   CA64082X2032

NERVGEN PHARMA CORP.

(NGEN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Bourse De Toronto
09/16/2021 09/17/2021 09/20/2021 09/21/2021 09/22/2021 Date
2.15(c) 2.18(c) 1.94(c) 1.93(c) 2 Last
14 413 14 154 37 270 6 229 32 637 Volume
-1.83% +1.40% -11.01% -0.52% +3.63% Change
More quotes
Estimated financial data (e)
Sales 2021 - - -
Net income 2021 - - -
Net Debt 2021 - - -
P/E ratio 2021 -
Yield 2021 -
Sales 2022 - - -
Net income 2022 - - -
Net Debt 2022 - - -
P/E ratio 2022 -
Yield 2022 -
Capitalization 78,5 M 61,6 M 61,4 M
Capi. / Sales 2021 -
Capi. / Sales 2022 -
Nbr of Employees -
Free-Float 88,0%
More Financials
Company
NervGen Pharma Corp. is a Canada-based biotechnology company. The Company is focused on developing solutions for the treatment of nerve damage and neurodegenerative diseases. The Company is also developing drugs for the treatment of spinal cord injury (SCI), multiple sclerosis (MS) and AlzheimerÔÇÖs disease. Its platform technology targets protein tyrosine phosphatase sigma (PTP sigma), a neural receptor that... 
More about the company
All news about NERVGEN PHARMA CORP.
09/15NERVGEN PHARMA : Grants Stock Options
PU
09/15888,750 Common Shares of NervGen Pharma Corp. are subject to a Lock-Up Agreement Ending..
CI
09/14NERVGEN PHARMA : A Glimpse into the Paralympics
PU
09/13NERVGEN PHARMA : Announces Results of Annual General Meeting of Shareholders
AQ
09/13Encode Ideas, L.P. Announces the Initiation of Research Coverage on NervGen Pharma Corp..
NE
09/13NERVGEN PHARMA : Presenting at the H.C. Wainwright 23rd Annual Global Investment Conferenc..
PU
09/10NervGen Pharma Corp. Appoints Krista Mckerracher and Glenn Ives to Its Board of Directo..
CI
08/31NERVGEN PHARMA : Chasing Dreams After Disability – MeetáThe Stubborn Baker
PU
08/19Nervgen Pharma Corp. Reports Earnings Results for the Second Quarter Ended June 30, 202..
CI
08/09NervGen Pharma Corp. and Massachusetts General Hospital Collaborate on Preclinical Stud..
CI
08/05NervGen Pharma Corp. announced that it has received CAD 2.343036 million in funding
CI
08/04NervGen Pharma Corp. announced a financing transaction
CI
08/03NERVGEN PHARMA : Train Airline Staff to Understand the Value of a Mobility Device and Mayb..
PU
07/20THE OUTDOOR DIARIES : Andy McKenna, Multiple Sclerosis and Mountain Biking
PU
07/19NERVGEN PHARMA : Grants Stock Options
AQ
More news
News in other languages on NERVGEN PHARMA CORP.

- No features available -

More news
Chart NERVGEN PHARMA CORP.
Duration : Period :
NervGen Pharma Corp. Technical Analysis Chart | NGEN | CA64082X2032 | MarketScreener
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 1,93 CAD
Average target price 6,00 CAD
Spread / Average Target 211%
Managers and Directors
Paul A. Brennan President, Chief Executive Officer & Director
William J. Adams Chief Financial Officer
William Joseph Radvak Executive Chairman
Daniel Mikol Chief Medical Officer
Michael Jeffrey Abrams Independent Director
Sector and Competitors
1st jan.Capi. (M$)
NERVGEN PHARMA CORP.-13.45%61
MODERNA, INC.315.47%175 199
LONZA GROUP AG33.09%60 866
IQVIA HOLDINGS INC.43.03%49 103
CELLTRION, INC.-23.26%31 708
SEAGEN INC.-5.78%30 021